After two successful vaccine tests, the Center decided to start the nationwide vaccination campaign on January 16, following the upcoming festivals, including Lohri, Makar Sankranti, Pongal, Magh Bihu etc., government sources said on Saturday. . The decision came after the Prime Minister chaired a high-level review meeting with the Cabinet Secretary, the PM’s Chief Secretary, the Secretary of Health and other senior officials to review the status of COVID-19 in the country, along with the preparation of the State / UTs for COVID vaccination. The prime minister will interact with all CMs on Monday about the same.
Army takes Chinese soldier into custody after he crossed to the Indian side of LAC
Vaccine launched on January 16
Priority will be given to health workers and frontline workers, estimated at around 3 crores in number, which are currently being registered in the government’s CO-Win App – 75 lakh beneficiaries already registered. Followed by those over 50 years of age and population groups under 50 with comorbidities of around 27 crores will be vaccinated by July. More than 61,000 program managers, 2 lakh vaccinators and 3.7 lakh other members of the vaccination team have so far been trained as part of training at state, district and bloc levels. The government has yet to make an official request to the manufacturer COVISHIELD – Serum Institute of India (SII), which has stocked 50 million doses for India.
Vaccine testing
With India’s COVID-19 count reaching 1.04.31.639 cases and active cases dropping to 2.24,190, the nation conducted its vaccine simulation in 700 districts in all states / UTs in India, except Uttar Pradesh and Haryana in 8 of January. In the previous vaccine trial, a total of 286 session locations spread across 125 districts were held on January 2. Both trials were successful and aimed at ensuring efficient planning and management for vaccine delivery in all states and territories in the Union, with Union Health Minister Dr. Harsh Vardhan reviewing the trial in Chennai earlier in the day.
PM Modi will chair the meeting of all CMs on January 11 to discuss the launch of the COVID-19 vaccine
DCGI nodded to COVISHIELD & COVAXIN
On Sunday, VG Somani, General Controller of Medicines of India (DCGI) announced that vaccines from Serum Institue of India (Covishield) and Bharat Biotech (Covaxin) have been given restricted use in an emergency situation. Covishield – a recombinant chimpanzee adenovirus vector vaccine – is 70.42% effective, with provisional safety and immunogenicity data from Phase II / III trials submitted to the SEC. 50 million doses were stored.
Meanwhile, Covaxin – a vaccine against corona virus inactivated with whole virus – 22,500 participants vaccinated in Phase III studies and was considered safe according to the data available to date. On Thursday, Bharat Biotech (BBL) said the company had completed its phase 3 enrollment for clinical trials with 25,800 participants. As informed by the ICMR, BBL has already administered 24,000 volunteers with the first injection of its vaccine and 5,000 have been administered with the second dose – with no adverse events found. 20 million doses have been stored and phase 3 trials of both vaccines are ongoing.
MP CM clarifies about the man’s death 10 days after the COVAXIN trial, calls this a ‘mistake’
COVAXIN completes the enrollment of 25,800 volunteers for phase 3 trials before the ‘trial’